Market GuidanceManagement updated its guidance to reflect market softness, the impact of the decommissioning of the company's legacy Costa Rican manufacturing facility, and the modest delay in Motiva FDA approval.
Sales GuidanceShares fell approximately 8% following the 3Q print due to lowered sales guidance for 2024 and ongoing weakness in certain markets.
Stock PerformanceESTA shares are still off -30% from highs achieved earlier in the year predominantly linked to ongoing market weakness across the aesthetics space.